Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
- Reva taps new regulatory VP
Reva Medical Inc. (ASX:RVA), which is developing a novel bioresorbable slide and lock drug-eluting coronary stent, called ReZolve, announced that Jeffrey Anderson joined the company’s executive team as vice president of clinical and regulatory affairs. Anderson brings almost 20 years of experience in the medical device industry and previously served in the same capacity for the company from 2004 to 2008. Prior to returning to Reva, he held positions of VP of regulatory & clinical affairs and VP of research and development for Neomend Inc., where he led the the company’s surgical-sealant products through the Food & Drug Administration’s pre-market approval process. Anderson also worked at Abbott Vascular, Jomed, CRS Clinical Research and Medtronic.
Read more - Welch Allyn adds two new directors
Welch Allyn announced that Greg Norden and Craig B. Reynolds have been elected by its shareholders to serve on the company’s board of directors. Norden and Reynolds join nine incumbent directors, including Chairman of the Board James Crook Jr., Welch Allyn President and CEO Julie Shimer, fourth generation family members Eric Allyn, Tasha Allyn Given and Peer Allyn Soderberg, MD, as well as Robert J. Bennett, Larry Buckelew, Yvonne Curl and Barry Wilson.
Read more - Avinger to double sales force
Redwood City-based Avinger Inc. plans to double the size of its sales force over the next several months by adding an additional 15 sales professionals. The company is preparing for an acceleration of growth following the successful achievement of key milestones. Avinger will continue developing the next generation of its commercialized products, Wildcat and Kittycat, which are indicated for use as guidewire support catheters. In March, Avinger plans to complete enrollment of its 88-patient CONNECT clinical trial which is intended to evaluate Wildcat’s ability to cross chronic total occlusions in femoropopliteal lesions. The expanded sales force will enable further reach into new locations throughout the U.S. to help treat more patients suffering from PAD, a disease that currently affects between 8 to 12 million adults and is the leading cause of amputation in patients over 50.
Read more - BrainScope appoints Dr. Peter Andrews to medical advisory board
Bethesda, Md.-based BrainScope company Inc. announced that Dr. Peter Andrews joined its medical advisory doard. He holds the distinguished title of Professor of Anaesthetics & Critical Care at the University of Edinburgh, Scotland. This appointment coincides with BrainScope’s recent announcement that it is entering the U.K. market with its "B-Ahead U.K. Trial," a multi-center, observational clinical study utilizing its technology in development to aid in the assessment of traumatic brain injury (TBI) and its milder forms (commonly referred to as "concussion") in emergency departments in the U.K.
Read more - OrthoAccel taps new scientific advisor
OrthoAccel Technologies Inc. announced that it has engaged Dr. Dawei Liu as a scientific advisor. Dr. Liu’s guidance and expertise will help advance the company’s commitment to a research-focused strategy for developing and introducing innovative new products. AcceleDent is a simple, removable dental appliance that an orthodontic patient wears in the mouth for 20 minutes daily to accelerate orthodontic tooth movement.